What Caught Our Attention: A big peer review (and perhaps academic mentorship) fail. These researchers used the wrong anticoagulant for their blood samples, leading them to believe that certain blood components were fighting microbes. The authors counted the number of colonies to show how well or poorly Tuberculin mycobacteria were growing in cultures — but blood samples need anticoagulants to prevent clots before analysis, and they used an anticoagulant that actually prevented the microbes from colonizing. The authors (and reviewers) should have known this from a 1999 CDC publication about the diagnosis of tuberculosis (echoed in virtually every public health pamphlet since), which explicitly says not to use their anticoagulant — ethylenediaminetetraacetic acid (EDTA) — if intending to culture the blood sample for mycobacteria.
At least the post-publication peer review process seemed to work…a year later.
Journal: Innate Immunity
Authors: Ramiro López-Medrano, José Manuel Guerra-Laso, Eduardo López-Fidalgo, Cristina Diez-Tascón, Silvia García-García, Sara Blanco-Conde, Octavio Miguel Rivero-Lezcano
Affiliations: Hospital Comarcal del Bierzo, León, Spain; Complejo Asistencial Universitario de León, (CAULE), León, Spain; Universidad de León, León, Spain; Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL), León, Spain
The authors did not realise that the use of EDTA created errors in the paper. Although mycobacteria remain alive in the presence of EDTA, the formation of visible colonies is inhibited, which affected the enumeration of colony forming units for the quantification of the antimicrobial activity. Consequently, the absence of colonies was erroneously interpreted as mycobactericidal activity. Due to this error the article’s main finding about the antimycobacterial activity detected in plasma is incorrect.
Date of Article: August 22, 2016
Times Cited, according to Clarivate Analytics’ Web of Science: Zero
Date of Notice: September 27, 2017
Like Retraction Watch? Consider making a tax-deductible contribution to support our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up on our homepage for an email every time there’s a new post, or subscribe to our daily digest. Click here to review our Comments Policy. For a sneak peek at what we’re working on, click here. If you have comments or feedback, you can reach us at email@example.com.